JPRN-jRCT2080222289未知3 期
DS-7113b phase III study A randomized double-blind comparison study with immediate release (IR) oxycodone in opioid-naive patients with cancer pain
DAIICHISANKYO Co.,Ltd.0 个研究点开始时间: 2013年11月14日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients receiving non-opioid analgesics for cancer pain, who have not been receiving opioid analgesics
- •- Patients whose VAS is >= 35 mm and judged necessary to be treated with strong opioid analgesics
- •- Patients with an ECOG Performance Status (PS) is =<3, etc.
排除标准
- •Patients with symptom(s)/finding(s) falling under the contraindications or relative contraindications stated in the package insert for oxycodone hydrochloride powder and morphine hydrochloride preparations, etc.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial which compares the safety and efficacy of chemotherapy (Rituximab and Bendamustine ) combined with Duvelisib, the study treatment, or a placebo in patients who have previously treated Indolent Non-Hodgkin Lymphoma.Indolent Non-Hodgkin LymphomaMedDRA version: 19.0Level: HLTClassification code 10029621Term: Non-Hodgkin's lymphomas unspecified histology indolentSystem Organ Class: 100000004851EUCTR2015-004033-28-PLInfinity Pharmaceuticals, Inc.600
进行中（未招募）
1 期
A clinical trial which compares the safety and efficacy of chemotherapy (Rituximab and Bendamustine ) combined with Duvelisib, the study treatment, or a placebo in patients who have previously treated Indolent Non-Hodgkin Lymphoma.Indolent Non-Hodgkin LymphomaMedDRA version: 19.0Level: HLTClassification code 10029621Term: Non-Hodgkin's lymphomas unspecified histology indolentSystem Organ Class: 100000004851EUCTR2015-004033-28-ESInfinity Pharmaceuticals, Inc.600
进行中（未招募）
1 期
A clinical trial which compares the safety and efficacy of chemotherapy (Rituximab and Bendamustine ) combined with Duvelisib, the study treatment, or a placebo in patients who have previously treated Indolent Non-Hodgkin Lymphoma.Indolent Non-Hodgkin LymphomaMedDRA version: 18.1Level: HLTClassification code 10029621Term: Non-Hodgkin's lymphomas unspecified histology indolentSystem Organ Class: 100000004851EUCTR2015-004033-28-PTInfinity Pharmaceuticals, Inc.600
进行中（未招募）
1 期
A clinical trial which compares the safety and efficacy of chemotherapy (Rituximab and Bendamustine ) combined with Duvelisib, the study treatment, or a placebo in patients who have previously treated Indolent Non-Hodgkin Lymphoma.EUCTR2015-004033-28-FRInfinity Pharmaceuticals, Inc.600
进行中（未招募）
1 期
A clinical trial which compares the safety and efficacy of chemotherapy (Rituximab and Bendamustine ) combined with Duvelisib, the study treatment, or a placebo in patients who have previously treated Indolent Non-Hodgkin Lymphoma.Indolent Non-Hodgkin LymphomaMedDRA version: 19.0Level: HLTClassification code 10029621Term: Non-Hodgkin's lymphomas unspecified histology indolentSystem Organ Class: 100000004851EUCTR2015-004033-28-DEInfinity Pharmaceuticals, Inc.600